Amniocentesis is a procedure utilized to diagnose fetal defects in the second trimester of pregnancy. A sample from the amniotic fluid near the fetus in the womb is accumulated from a pregnant woman's abdomen using a syringe and needle. According to BlueQuark the Global Amniocentesis Needle Market is expected to grow considerably during the forecasted period. Factors such as the increasing burden of congenital diseases and the high reliability of people on amniocentesis are expected to drive the Amniocentesis Needle Market in the forecasted period. Further, a rising focus on healthcare technological advancements for developing new and advanced products and rising demand for marginally invasive surgeries is predicted to drive the Amniocentesis Needle Market in the forecasted period. Furthermore, a rise in pregnancy rate, an increase in preference for minimally and non-invasive diagnostic procedures, and high acceptance of diagnostic tests are expected to drive the Amniocentesis Needle Market in the forecasted period. However, high procedural costs will further derail the market growth rate. Unfavourable reimbursement scenarios and a lack of awareness in developing and underdeveloped economies will also pose market challenges. The low availability of advanced diagnostic equipment in backward economies will also hinder market growth.

The upsurge in the prevalence of genetic disorders globally is the primary factor fostering market growth. Rising concern about genetic diseases is the primary factor responsible for the growing number of procedures. Various studies have been conducted by organizations such as the National Institute of Health to understand the risks associated with amniocentesis procedures and the challenges during the same. Studies have revealed that early abortion after amniocentesis is a significant risk, and its prevalence is around 10%. However, with the technical advancements in needles and the focus of medical professionals on the safety of the patient, it is expected that the instances of early abortions will be reduced soon.

Furthermore, the increasing birth rate globally is enhancing market growth. The Amniocentesis needle suits females with a standard body mass index (BM) of 18.50-24.90 kgm2. There is a surge in the proportion of women who are overweight, but this portion will still be lesser than that of women with average weight. This is one of the significant features responsible for the massive share of 100-150 mm needles in the amniocentesis needles market. The amniocentesis procedure is the most generally recommended forward prenatal diagnostic test to find chromosomal disorders, infections, or congenital disabilities. Despite a small proportion of risks associated with this procedure, amniocentesis is carried out to detect the abnormalities in the developing fetus. Due to the increasing birth rate, rising number of amniocentesis procedures, growing adoption, and increasing focus on patient safety, the amniocentesis procedure segment is expected to show steady growth over the forecast period.

The global amniocentesis needle market is dominated by North America and Europe, respectively. North America will continue to influence the global market over the forecast period. Factors such as rising government initiatives and an increasing number of amniocentesis procedures are driving market growth in this region. The developed healthcare system in the United States is augmenting the demand for advanced products, which is accelerating the development of amniocentesis needles with cutting-edge technology. Additionally, a concern of the general population in the North American region about genetic disorders in a newborn is propelling the demand for amniocentesis procedures. The hospital's segment is awaited to account for a significantly huge revenue share in the global amniocentesis needle market during the forest period. This is attributed to the rapid expansion and increasing use of amniocentesis needles in the hospital sector. Hospitals frequently use amniocentesis, a prenatal technique, to identify fetal anomalies and genetic illnesses.

Demand for amniocentesis needles is directly impacted by the volume of operations carried out in hospitals, which serve as the principal healthcare venues where pregnant women get prenatal care. Healthcare practitioners prefer them over disposable needles since they are less expensive, especially in developing countries. The drawback of conventional needles is the possibility of contamination and infection, which can result in significant health issues. To reduce these hazards, healthcare personnel must adhere to precise sterilization processes and rules, which can be time-consuming and expensive. Throughout the projection period, the disposable needle sector is anticipated to have the fastest revenue Growth. This is attributable to growing public knowledge of the advantages of using disposable needles, including their convenience, ease of use, lower risk of infection, and reduced danger of contamination. Healthcare workers in affluent countries, where patient safety is paramount, likewise prefer disposable needles. Disposable needles are in higher demand due to their ability to reduce the danger of needlestick injuries, the spread of infectious diseases, and the increasing prevalence of infectious diseases like HIV and hepatitis. The introduction of novel and safer disposable needles into the market has been made possible by the development of improved materials and technology. This is another reason why the disposable needle segment is predicted to experience significant growth. Speciality needles, including coaxial, fine, and cutting needles, are part of the other sector. Due to the rising need for sophisticated and specialized operations in obstetrics and gynaecology, this segment is anticipated to expand over the projected period. These needles are made specifically for foetal reduction, selective abortion, and blood sampling. Moreover, the rising demand for barely invasive procedures is anticipated to drive the expansion of this market, as speciality needles allow medical professionals to carry out these procedures with more accuracy and precision.

The market players are Medtronic, CooperSurgical, Inc., RI.MOS. Srl, Integra LifeSciences Corporation., and Smiths Group plc.

In March 2021, Becton, Dickinson and Company announced the launch of a new amniocentesis needle - BD Chorionic Villus Sampling (CVS) System - that features an innovative ergonomic handle design to minimize hand fatigue and provide greater accuracy during procedures.

In February 2021, Biopsybell Srl announced the launch of its new amniocentesis needle - the BBsafe Midi-Amniocentesis Needle - which features an exact and sharp tip for improved sample collection and reduced trauma to the fetus.

Global Amniocentesis Needle Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Global Amniocentesis Needle Market by segmenting based on By Type (100 –150 mm Needles, Larger Than 150 mm Needles and Smaller Than 100 mm Needles), Procedure (Amniocentesis Procedures, Amnioreduction Procedures, Foetal Blood Transfusion Procedures, Amnioinfusion Procedures and Cordocentesis Procedures), End-User Industry (Hospitals, Diagnostic Centres, Clinics and Other End Users), and Geography (Asia-Pacific, North America, Europe, South America, and the Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.